Trovagene declares activation of 2 supplementary Clinical Trial sites to conduct Phase 1b/2 Study

Precision medicine biotechnology company, developing targeted oncology therapeutics, Trovagene asserted the addition of two leading  institutions,Yale Cancer Center and principal investigator Amer M. Zeidan, MBBS, MHS, and Kansas University Cancer Center and principal investigator Tara Lin, MD, to conduct its Phase 1b/2 open-label, multicenter trial of PCM-075 in patients with Acute Myeloid Leukemia .

Tara Lin, MD, Associate Professor of Medicine, Kansas University Cancer Center said “We are excited to be part of this important clinical trial in AML, an aggressive, and often difficult-to-treat cancer for which there are limited treatment options for patients who have relapsed or refractory disease.”

The open-label, multicenter Phase 1b/2 trial is designed to evaluate the safety of PCM-075 in combination with either low-dose cytarabine or decitabine in patients with Acute Myeloid Leukemia (AML) and to identify the maximum tolerated dose (MTD) in Phase 1b to administer to further evaluate the safety and preliminary efficacy in Phase 2.